M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells

Gain-of-function mutations in Kit receptor tyrosine kinase result in the development of a variety of cancers, such as mast cell tumours, gastrointestinal stromal tumours (GISTs), acute myeloid leukemia, and melanomas. The drug imatinib, a selective inhibitor of Kit, is used for treatment of mutant K...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Hara, Yasushi, Obata, Yuuki, Horikawa, Keita, Tasaki, Yasutaka, Suzuki, Kyohei, Murata, Takatsugu, Shiina, Isamu, Abe, Ryo
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2017
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5389679/
https://ncbi.nlm.nih.gov/pubmed/28403213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0175514
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items